Amplia AGM to be held Thursday 24 August 2023
Released
Released
Announcement PDF
ASX RELEASE
19 June 2023
Annual General Meeting to be held Thursday 24 August 2023
Amplia Therapeutics Limited (ASX: ATX) (‘Amplia’ or the ‘Company’) advises that its Annual General
Meeting in respect of its financial year ended 31 March 2023 is to be held on Thursday 24 August 2023.
Details of the meeting venue and other meeting arrangements will be confirmed at a later date.
In accordance with ASX Listing Rule 14.3 nominations for the election of Directors must be received by
the Company not later than Thursday 6 July 2023.
This ASX announcement was approved and authorised for release by the Company Secretary.
Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com
Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital
+61 423 139 163
About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal
Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the
field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as
pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic
pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter
(@ampliatx) and LinkedIn.
Level 17, 350 Queen St, Melbourne VIC 3000
Email info@ampliatx.com
www.ampliatx.com
Share your feedback
Discover